Volume 17, Number 10,
Issue of May 15, 1997
pp. 3840-3846
Copyright ©1997 Society for Neuroscience
Behavioral and Neurochemical Recovery from Partial
6-Hydroxydopamine Lesions of the Substantia Nigra Is Blocked by Daily
Treatment with D1/D5, But Not D2, Dopamine Receptor Antagonists
Received Dec. 23, 1996; revised Feb. 18, 1997; accepted Feb. 21, 1997.
Adriana Emmi,
Heshmat Rajabi, and
Jane Stewart
Center for Studies in Behavioral Neurobiology, Department of
Psychology, Concordia University, Montreal, Quebec, Canada H3G 1M8
To determine whether D1/D5 dopamine (DA) receptors play a role in
normalization of DA extracellular levels of striatal DA and behavioral
recovery after partial 6-OHDA lesions of the substantia nigra, animals
were treated on days 1-8 after lesioning with the D1/D5 DA receptor
antagonists SCH 23390 (0.1 mg/kg, s.c.) and SCH 39166 (1.0 mg/kg,
s.c.), the inactive enantiomer SCH 23388 (0.1 mg/kg, s.c.), the D2
antagonist eticlopride (0.1 mg/kg, i.p.), or saline. Spontaneous
turning behavior was assessed on days 3 and 15. Basal extracellular DA
and metabolites were measured in both striata using microdialysis on
days 16 and 17, 8-9 d after termination of drug treatments. On day 3, all animals turned ipsilateral to the lesion. On day 15, animals
previously treated with either saline, eticlopride, or SCH 23388 showed
no behavioral asymmetries, whereas animals treated with SCH 23390 or
SCH 39166 turned ipsilaterally. On days 16 and 17, extracellular DA did
not differ on the two sides in animals treated with saline or
eticlopride and were higher on the lesioned side after SCH 23388. In
animals treated with the D1/D5 receptor antagonists, however, basal
levels of DA were lower on the lesioned side, showing no evidence of
normalization. These results suggest a role for the D1/D5 DA receptor
in the development of compensatory changes in the DA neurons that
accompany behavioral recovery from partial lesions of nigrostriatal DA
system.
Key words:
substantia nigra;
6-OHDA lesions;
behavioral recovery;
striatal dopamine;
microdialysis;
D1/D5 receptor antagonists;
D2
receptor antagonists